Phase 1 dose escalation study of the MDM2 inhibitor milademetan as monotherapy and in combination with azacitidine in patients with myeloid malignancies.

Courtney D D DiNardoRebecca OlinEunice S WangBarry SkikneJoseph RosenthalPrasanna KumarHiroyuki SumiYoshiyuki HizukuriYing HongParul PatelTakahiko SekiTao DuanArnaud LesegretainMichael Andreeff

Published in: Cancer medicine (2024)

Milademetan was relatively well tolerated in this population; however, despite signals of activity, clinical efficacy was minimal.

Keyphrases

acute myeloid leukemia
open label
dendritic cells
bone marrow
randomized controlled trial
clinical trial
combination therapy
study protocol